The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
[EN] NUCLEAR RECEPTOR BINDING AGENTS<br/>[FR] AGENTS DE LIAISON DE RECEPTEUR NUCLEAIRE
申请人:GTX INC
公开号:WO2007062230A2
公开(公告)日:2007-05-31
[EN] The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity. [FR] L'invention concerne une nouvelle catégorie de modulateurs sélectifs des récepteurs oestrogéniques (SERM). Ces composés SERM peuvent servir dans la prévention et/ou le traitement d'une pluralité de maladies et d'états, y compris pour prévenir et traiter des cancers tels que le cancer de la prostate et du sein, l'ostéoporose, des maladies hormonales, des bouffées de chaleur ou des symptômes vasomoteurs, des troubles neurologiques, des maladies cardio-vasculaires et l'obésité.